Pereiti prie pagrindinio turinio

Adresas

Panerių g. 246
48454 Kaunas
Lietuva

Darbo laikas

  • Pi – Pe
    9 :00 – 17 00
  • Še  
    Nedirbame    
  • Se
    Nedirbame   
Dog DNA testing illustration

Progressive Retinal Atrophy (crd4-PRA/cord1)

Kodas: H766

74,72 €

Mėginio duomenys

Vienas tyrimas – vienas mėginys. Gyvūno ir savininko duomenys neprivalomi.

Ieškokite pagal mūsų ar laboratorijos numerį. Nerastas numeris išsaugomas kaip ankstesnis / išorinis numeris. Naujo fizinio mėginio nereikia.
Įdėjimo į krepšelį mygtukas pasirodys po to, kai aukščiau pasirinksite reikšmę

Short description

Progressive Retinal Atrophy (PRA) is a large group of genetic diseases in which the retina gradually degenerates over time, causing a progressive loss of vision.

General information

Progressive Retinal Atrophy (PRA) is a large group of genetic diseases in which the retina gradually degenerates over time, causing a progressive loss of vision. This variant of the disease, known as crd4-PRA, or as cord1, occurs in the Dachshund and the English Springer Spaniel. It is caused by an autosomal recessive mutation to the retinitis pigmentosa GTPase regulator-interacting protein 1 (RPGRIP1) gene.

Specifications

Breeds

Dachshund, English Springer Spaniel

Gene

RPGRIP1

Chromosome

15

Mutation

c.142_143ins

Organ

Sensory organs

Specimen

Swab, Blood EDTA, Blood Heparin, Semen, Tissue

Mode of Inheritance

Autosomal Recessive

Also known as

cord1; crd4; PRA-crd4

Clinical features

The disorder that primarily affects the retina, leads to the progressive loss of cone and rod photoreceptor cells. Early signs of eye problems can appear by 6 months of age. However, the age at which dogs start to lose their sight varies a lot. On average, sight loss begins around 5 years old. Some dogs may be blind by 6 months, while others can still see at 10 years old.

Additional information

Research demonstrate the interaction of two independent loci (RPGRIP1 and MAP9) contribute to the canine PRA phenotype. To be more specific, a mutation in RPGRIP1 alone does not always appear to be sufficient to cause PRA. An additional mutation in MAP9 may be required for the (full) clinical manifestation of the disease. This suggests a modifying role of MAP9 in the progression of the disease. The mutation in MAP9 is analysed in a separate test.

References

Pubmed ID: 16806805

Year published: 2006

Omia ID: 1432

Omia variant ID:

Turnaround information

  • 10 working days